


**Supplementary Figure 1.** *Upper panels*: Immature MDDCs were identified as CD14-CD11c<sup>+</sup> CD80<sup>low/null</sup> (green histogram) while mature MDDCs were CD11c<sup>low</sup> CD80<sup>high</sup> (blue histogram). *Lower panel*: MDDCs maturation was assessed measuring the expression of CD80 and CD38.



**Supplementary Figure 2.** (A) Highly enriched naïve CD4<sup>+</sup> purity was assessed using CD45RA and CCR7 antibody. (B) Treg were identified as CD25<sup>high</sup>CD127<sup>low</sup>Foxp3<sup>+</sup>. (C) Th1 cells were identified as Tbet<sup>+</sup>IFN $\gamma^+$ . (D) Th17 cells were identified as Ror $\gamma$ t<sup>+</sup>IL17<sup>+</sup>.

**Supplementary Table 1A.** Univariate and multivariate logistic regression analysis to individuate the variables independently associated with CD80 expression on mMDDCs.

	Univariate Analysis		Multivariate Analysis	
	HR (CI 95%)	p	HR (CI 95%)	р
Age	1.05 (1.01–1.09)	0.008	1.02 (0.96–1.08)	0.44
Sex	0.45 (0.18-1.08)	0.07	1.46 (0.44–4.9)	0.53
NSTEMI diagnosis	2.61 (1.21-5.65)	0.001	2.28 (0.79-6.57)	0.02 *
Familial History of IHD	0.72 (0.33–1.56)	0.4		
Hypertension	1.57 (0.74–3.33)	0.24		
Hypercolesterolemia	1.16 (0.55–2.45)	0.7		
Smoke	1.14 (0.53–2.41)	0.7		

Diabetes	2.61 (0.6–10.4)	0.17		
Statin treatment	1.11 (1.02–1.21)	0.01	1.08 (0.98-1.21)	0.11
ACE-inhibitor/ARB treatment	0.80 (0.24–2.68)	0.73		
Oral antidiabetics/insulin treatment	0.97(0.86-1.09)	0.63		
Acetylsalicylic acid treatment	0.76 (0.20-2.78)	0.67		

The analysis included 18 NSTEMI patients, 16 SA patients and 16 HC subjects. **IHD** = ischemic heart disease; **ARBs** = Angiotensin II receptor blockers. \* Only the diagnosis of NSTEMI at the time of study enrollment was independently associated with CD80 expression on mMDDCs.

**Supplementary Table 1B.** Univariate and multivariate logistic regression analysis to individuate the variables independently associated with IDO mRNA expression in mMDDCs.

	Univariate Analysis		Multivariate Analysis	
	HR (CI 95%)	p	HR (CI 95%)	p
Age	1.02 (0.96–1.07)	0.48	1.00 (0.94–1.07)	0.85
Sex	0.57 (0.18–1.77)	0.3	0.76 (0.20-2.78)	0.67
NSTEMI diagnosis	5.6 (2.24–14.9)	0.001	3.32 (1.02–10.8)	0.04*
Familial History of IHD	1.3 (0.27–6.19)	0.7		
Hypertension	0.5 (0.16–1.57)	0.23		
Hypercolesterolemia	1.35 (0.33–5.42)	0.6		
Smoke	0.87 (0.27–2.75)	0.81		
Diabetes	2.8 (0.96-8.13)	0.06		
Statin treatment	2.8 (0.96-8.13)	0.05	2.0 (0.6-6.9)	0.26
ACE-inhibitor/ARB treatment	1.00 (0.88–1.13)	0.94		
Oral antidiabetics/insulin treatment	1.02 (0.96-1.07)	0.48		
Acetylsalicylic acid treatment	0.57 (0.18–1.77)	0.3		

The analysis included 18 NSTEMI patients, 16 SA patients and 16 HC subjects. **IHD** = ischemic heart disease; **ARBs** = Angiotensin II receptor blockers. \* Only the diagnosis of NSTEMI at the time of study enrolment was independently associated with IDO mRNA expression in mMDDCs.